首页   按字顺浏览 期刊浏览 卷期浏览 Substance P (Neurokinin-1) Antagonist Prevents Postoperative Vomiting after Abdominal H...
Substance P (Neurokinin-1) Antagonist Prevents Postoperative Vomiting after Abdominal Hysterectomy Procedures

 

作者: Zsuzsanna Gesztesi,   Phillip Scuderi,   Paul White,   William Wright,   Ronald Wender,   Robert D’Angelo,   L. Black,   Patricia Dalby,   David MacLean,  

 

期刊: Anesthesiology  (OVID Available online 2000)
卷期: Volume 93, issue 4  

页码: 931-937

 

ISSN:0003-3022

 

年代: 2000

 

出版商: OVID

 

关键词: Drug interactions;emesis;ondansetron.

 

数据来源: OVID

 

摘要:

BackgroundThe safety and antiemetic efficacy of CP-122,721, a novel neurokinin-1 antagonist, was evaluated when administered alone or in combination with ondansetron.MethodsUsing a randomized, double-blind, placebo-controlled study design, CP-122,721 was initially compared with placebo and subsequently to ondansetron alone and in combination for prophylaxis against postoperative nausea and vomiting in 243 women undergoing abdominal hysterectomy. In the dose-ranging studies (n = 86), patients received either CP-122,721 100 mg (vs. placebo) or 200 mg (vs.placebo) orally 60–90 min before induction of anesthesia. In the interaction study (n = 157), patients received CP-122,721 200 mg or placebo 60–90 min before induction of anesthesia, and ondansetron 4 mg or saline 2 ml intravenously 15–30 min before the end of surgery. Patients assessed their level of nausea and pain on arrival in the postanesthesia care unit and at 0.5-, 1-, 1.5-, 2-, 4-, 8-, 12-, and 24-h intervals postoperatively. Emetic episodes, need for rescue antiemetic–antinausea medication, postoperative complications, and patient satisfaction were recorded.ResultsIn the initial dose-ranging study, only 10% of the patients experienced emesis within the first 8 h after surgery with CP-122,721 200 mg compared with 50% in the placebo group. CP-122,721 200 mg also decreased the need for rescue medication (25%vs.48%). CP-122,721 100 mg was less effective than 200 mg in decreasing the incidence of repeated episodes of emesis. In the interaction study, 6% of the patients receiving CP-122,721 200 mg orally experienced emesis less than 2 h after surgery compared with 17% with ondansetron alone. With combined therapy, only 2% experienced emesis. In addition, the median times for 75% of patients to remain free from postoperative nausea and vomiting were 82, 75, and 362 min in the ondansetron, CP-122,721, and combination groups, respectively.ConclusionsOral CP-122,721 200 mg decreased emetic episodes compared with ondansetron (4 mg intravenously) during the first 24 h after gynecologic surgery; however, there was no difference in patient satisfaction.

 

点击下载:  PDF (166KB)



返 回